drugset / Trial / NCT07498205
Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare momelotinib and ruxolitinib as treatments for myelofibrosis with low blood cell counts. Both drugs are approved by the FDA to treat myelofibrosis. The study asks which drug does a better job at shrinking the spleen.
Timeline
- Start
- 2026-08-08
- Primary completion
- 2029-08-08
- Completion
- 2031-08-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Momelotinib | Small molecule | 200 mg | — |
| Comparator | Ruxolitinib | Small molecule | — | — |